Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bo Kruse Insider Profile
4 Followers
Bo Kruse, EVP, CFO, SECRY & TREAS at Y-Mabs Therapeutics, holds 210.88K shares in Y-Mabs Therapeutics (Ticker: YMAB).
Bo Kruse Y-Mabs Therapeutics (YMAB)EVP, CFO, SECRY & TREAS
Y-Mabs Therapeutics (YMAB)
EVP, CFO, SECRY & TREAS
Ranked #45,961 out of 97,997 Corporate Insiders
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
+4.20%
Average return per transaction
Time Frame
Compare to
Insider Roles
EVP, CFO, SECRY & TREAS
Roles that Bo Kruse holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:May 15, 2020 - May 15, 2021
Return:+11.40%
The most profitable trade made by Bo Kruse
Bo Kruse's Trading History
List of latest transactions for each holding click on a transaction to see Bo Kruse's performance on stock
You May Also Like
Bo Kruse insider profile FAQ
What is the percentage of profitable transactions made by Bo Kruse?
The percentage of profitable transactions made by Bo Kruse is 50%.
What is the average return per transaction made by Bo Kruse?
The average return per transaction made by Bo Kruse is 4.20%.
What stocks does Bo Kruse hold?
Bo Kruse holds: YMAB stocks.
What was Bo Kruse’s latest transaction?
Bo Kruse latest transaction was an Uninformative Buy of $120.00K.
What was Bo Kruse's most profitable transaction?
Bo Kruse’s most profitable transaction was an Informative Sell of YMAB stock on May 15, 2020. The return on the trade was 11.40%.
What is Bo Kruse's role in Y-Mabs Therapeutics?
Bo Kruse's role in Y-Mabs Therapeutics is EVP, CFO, SECRY & TREAS.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.